AvenCell Therapeutics has raised $112 million in Series B financing to support the development of both autologous and allogeneic switchable CAR-T cell therapies.   The financing was led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital and NYBC Ventures also participated in the round alongside […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!